A 61-year-old man with the chief complaint of pressure with swallowing was referred to our hospital with type 3 cardiac
gastric cancer. Gastrofiberscope showed type 3
cardiac cancer with esophageal invasion. On the abdominal computed tomography, there was evidence of lymph node swelling in the lesser curvature and multiple liver
metastases. Blood
tumor markers were elevated: CEA 200 ng/mL, CA19-9 2,490 U/mL. He was diagnosed as unresectable advanced
gastric cancer UE-circ, type-3, c-T3N2H1P0M1, Stage IV. A biopsy revealed
adenocarcinoma (tub2-por1). We started bi-weekly
docetaxel and
S-1 combination chemotherapy(DOC 40 mg/m2 day 1, 14, S-180 mg/m2 day 1-7, 14-21). After completion of the first course of this combination
therapy, his feeling of pressure was relieved and CT showed reduction of multiple liver lesions and
lymph node metastases, indicating partial response. No regrowth was seen for 7 courses of the
therapy. Regarding toxicity, grade 2
nausea and grade 1 nail
pain were observed. After 7 courses, because of serum CEA elevation, bi-weekly
CPT-11/CDDP
therapy (
CPT-11 60 mg/m2, CDDP 30 mg/m2) was administered followed by weekly PTX
therapy (65 mg/m2 day 1, 7, 14; total of 4 weeks). To date, 17 months after administration of
chemotherapy, he has been treated on an outpatient basis. Biweekly DOC/S-1
therapy can be novel antitumor
therapy which can be conducted safely in an outpatient setting for advanced
gastric cancer.